341 results on '"Kanao, Kent"'
Search Results
2. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
3. Complete response to pembrolizumab in a patient with recurrent and metastatic urothelial bladder carcinoma reflecting coexisting sarcomatoid subtype and glandular differentiation: a case report
4. Choroidal Metastasis From Papillary Renal Cell Carcinomas: A Case Report and a Review of the Literature
5. Safety of adjuvant gemcitabine plus cisplatin chemotherapy in a patient with bilateral ureteral cancer undergoing hemodialysis
6. Clinical pharmacokinetics of flomoxef in prostate tissue and dosing considerations for prostatitis based on site-specific pharmacodynamic target attainment
7. Reduced port laparoscopic radical nephrectomy using an umbilical zigzag skin incision for renal cell carcinoma
8. New risk stratification for adjuvant nivolumab for high‐risk muscle‐invasive urothelial carcinoma.
9. Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: Dosing considerations for prostatitis
10. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma
11. Impact of a robotic surgical system on treatment choice for men with clinically organ-confined prostate cancer
12. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy
13. External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study
14. Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis
15. Penetration of piperacillin–tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics
16. Impact of an Adjuvant Chemotherapeutic Regimen on the Clinical Outcome in High Risk Patients with Upper Tract Urothelial Carcinoma: A Japanese Multi-Institution Experience
17. Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone
18. Complete response to pembrolizumab in a patient with recurrent and metastatic urothelial bladder carcinoma reflecting coexisting sarcomatoid subtype and glandular differentiation: a case report
19. Axitinib-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic renal cell carcinoma
20. Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
21. Novel algorithm for management of acute epididymitis
22. Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib
23. A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio for Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy
24. Independent Predictors for Bladder Outcomes after Treatment of Intravesical Recurrence following Radical Nephroureterectomy in Patients with Primary Upper Tract Urothelial Carcinoma
25. Metastatic Behavior of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: Association with Primary Tumor Location
26. IMPACT OF MAXIMUM TUMOR DIAMETER ADJUSTED BY PRIMARY TUMOR LOCATION IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA MANAGED BY RADICAL NEPHROURETERECTOMY: THE MULTI-INSTITUTIONAL STUDY: MP27-18
27. CAN SMALL LESIONS OF GLEASON 3+4 BE LEFT UNTREATED IN FOCAL THERAPY? ANALYSIS OF RADICAL PROSTATECTOMY SPECIMENS.: MP18-14
28. Optimal method for measuring tumor extent in needle biopsy specimens to identify small-volume prostate cancer
29. Comparative investigation on clinical outcomes of robot-assisted radical prostatectomy between experienced open prostatic surgeons and novice open surgeons in a laparoscopically naïve center with a limited caseload
30. PD47-04 PATHOLOGICAL FEATURES OF THE INDEX AND NON-INDEX LESIONS IN RADICAL PROSTATECTOMY SPECIMENS: IMPLICATIONS FOR FOCAL THERAPY.
31. Efficacy of Abiraterone Acetate For High-Risk Hormone-Naïve Metastatic Prostate Cancer: A Comparison With Combined Androgen Blockade Therapy With Bicalutamide And Androgen Deprivation Therapy Alone
32. Carcinoma ex pleomorphic adenoma of the submandibular gland with renal metastases composed exclusively of metastasizing pleomorphic adenoma
33. Surgical site infection risk factors identified by multivariate analysis for patient undergoing laparoscopic, open colon, and gastric surgery
34. Individualized Prostate-specific Antigen Threshold Values to Avoid Overdiagnosis of Prostate Cancer and Reduce Unnecessary Biopsy in Elderly Men
35. Prognostic value of preoperative multiparametric magnetic resonance imaging (MRI) for predicting biochemical recurrence after radical prostatectomy
36. THE PREDICTIVE VALUE OF C-REACTIVE PROTEIN FOR PROGNOSIS IN PATIENTS WITH METASTATIC UPPER TRACT UROTHELIAL CARCINOMA TREATED WITH CISPLATIN-BASED CHEMOTHERAPY FOLLOWING RADICAL NEPHROURETERECTOMY: MULTI-INSTITUTIONAL STUDY: MP77-19
37. CHARACTERIZING THE DOMINANT/INDEX LESION IN PROSTATE CANCER: IMPLICATIONS FOR GRADING AND STAGING: PD15-01
38. DEVELOPMENT OF AN ALGORITHM FOR PREDICTING SEVERE ACUTE EPIDIDYMITIS: MP16-18
39. Laparoendoscopic single‐site simple nephrectomy and reduced port procedure for inflammatory nonfunctioning kidney
40. Can transrectal needle biopsy be optimised to detect nearly all prostate cancer with a volume of ≥0.5 mL? A three-dimensional analysis
41. Interleukin 6 Is Associated with Cachexia in Patients with Prostate Cancer
42. Surgical site infection surveillance after open gastrectomy and risk factors for surgical site infection
43. Discontinuation of first-line molecular-targeted therapy and prognosis in patients with metastatic renal cell carcinoma: Impact of disease progression vs. adverse events
44. Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: the experience of Japanese multi-institutions
45. PREDICTIVE VALUE OF POSITIVE URINE CYTOLOGY FOR PROGNOSIS IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA FOLLOWING RADICAL NEPHROURETERECTOMY: 399
46. CHARACTERISTICS AND OUTCOME IN METASTATIC UPPER TRACT UROTHELIAL CARCINOMA FOLLOWING RADICAL NEPHROURETERECTOMY: THE MULTI-INSTITUTIONAL EXPERIENCE: 398
47. Transurethral lithotripsy with holmium-YAG laser of a large exogenous prostatic calculus
48. Prognostic Significance of High Nuclear Grade in Patients with Pathologic T1a Renal Cell Carcinoma
49. The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: A multi-institutional study
50. Dorsal Vein Complex Preserving Technique During Robot-Assisted Radical Prostatectomy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.